Mesoblast Gains Ethics Approval to Treat Australian COVID-19 Patients

September 02, 2020 12:30 PM AEST | By Team Kalkine Media

Google News:

Recent News

CLO Virtual Fashion Acquires swatchbook, Solidifying Leadership in Dig...

CKGSB Launches New White Paper on China's Role in the Global AI Race

JA Solar Wins RETC "Overall Highest Achiever" Award for the Sixth Cons...

HIGHWAY HOLDINGS REPORTS FISCAL FOURTH QUARTER AND FULL YEAR 2025 RESU...

ASX 200 listed global leader in allogeneic cellular medicines for inflammatory diseases, Mesoblast Limited (ASX:MSB) has obtained ethics approval to involve Australian hospitals in the Phase 3 trial of remestemcel-L in ventilator-dependent COVID-19 patients with ARDS.

Participating hospitals in Sydney and Melbourne have been approved by the Human Research Ethics Committee of Monash Health and shall join over 17 leading US medical centers already in the Phase 3 trial.

This study is cleared by the US FDA and being conducted by the US National Institutes of Health-funded Cardiothoracic Surgical Trials Network.

On 2 September 2020, MSB share price was noted at A$5.240 at AEST 11:47 AM.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.